specialist teams that direct care and coordination, teach self management strategies, refer to support services, and help patients navigate the health care system have been associated with improved health outcomes for people with prevalent conditions 1, 2 such as asthma [3] [4] [5] and AIDS. 6, 7 Lasker outlined the value of these medical and public health partnerships. 8 This article demonstrates how successful partnerships among health care professionals, consumers, and government agencies have created a nationwide regional health delivery system that has optimized access to care and prevention services and improved health outcomes for people with hemophilia in the United States. Elements of the chronic care model, described elsewhere, [9] [10] [11] include community resources and policies, health care organizations, selfmanagement support, delivery system design, and clinical information systems and are exemplified by our nationwide system of hemophilia care. Hemophilia is an inherited bleeding disorder that primarily affects males and is characterized by bleeding into joints and muscles. Hemorrhages into the head, throat, and gastrointestinal areas can be fatal. Although not curable, hemophilia can be treated by replacing, via intravenous infusion, the missing proteins needed for clotting. Hemophilia is diagnosed at birth, and treatment lasts a lifetime. Hemophilia affects about 18 000 Americans of all racial and ethnic backgrounds. 12 The article by Katon et al. 1 on redefining practitioner roles in caring for people with complex, severe, and persistent disorders applies to people with hemophilia. The most successful treatment and care interventions require an organized multidisciplinary approach. Thirty years ago, parents faced with the crippling and possible death of their hemophilic children formed a bond with their physicians that led to the development of an extremely effective health advocacy collaboration. That partnership created a nationwide hemophilia health delivery system that has grown beyond medical care to include research and the public health functions of needs assessment, capacity building, surveillance, prevention, and policy. 13 Unique characteristics of the US hemophilia model are as follows: (1) 
History of the Regional System of Care and Outcomes
In 1975, through advocacy efforts led by those who treated hemophilia and parents affiliated with the consumer advocacy organization, the National Hemophilia Foundation (NHF), and based on the experience of early novel multidisciplinary approaches in Britain 15 and California, 16 Congress provided sup- • Mortality rates and hospitalization rates 40% lower among hemophilia patients seen in federally funded HTCs FIGURE 1-Outcomes of comprehensive care at US hemophilia treatment centers.
a 40% reduction in bleed-related hospitalizations 21 among men who used an HTC at least once in the 3-year study period. These decreases occurred despite the HTC cohort having more severe symptoms and higher proportions of HIV and hepatitis than peers who obtain their care outside the HTC network ( Figure 1 27 Twenty-nine percent of HTC patients were female, and 27% were non-white. 27 More than 5000 HTC patients had hepatitis C, 31 and 1600
had HIV. 27 Only 4% had no insurance. 27 The US HTCs conducted 14 151 annual evaluations, provided another 18 051 comprehensive examinations, gave 1903 consults, conducted 7759 diagnostic exams, and provided 7380 education seminars to groups separate from 1-on-1 teaching in clinic. 27 HTCs monitor universal precautions with the 9119 people who they taught to self-infuse their medication. 27 They reported that 21103 patients had a primary care practitioner; HTCs sent written summaries to 73% of them. 27 HTCs enrolled over 16 000 of their patients (including 12 480 or 87% of patients with hemophilia) in the CDC's nationwide prospective surveillance study to monitor hemophilia complications, logging more than 42 000 study visits since that study began 1998.
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Federal grants partially support salaries of HTC core staff to provide comprehensive care (HRSA) and to conduct research and provide prevention services (CDC) to monitor and prevent 2 main hemophilia complications: blood-borne viruses and
Regional office = FIGURE 2-US Hemophilia Treatment Center regions. joint disease. Both agencies share as their top goal enhanced access to the regional network of HTCs. HRSA-specific goals for HTCs are as follows: (1) to provide care that is family centered, culturally competent, community based, and easy to use; (2) to strengthen services to women, minorities, adolescents, the geographically distant, and the insurance restricted; (3) to encourage consumer partnership in decision making; (4) to conduct outreach and education; (5) to emphasize prevention; (6) to collaborate with health agencies; and (7) to link patients with primary care practitioners. The CDC-specific goals for HTCs are as follows: (1) to prevent complications through assessment, surveillance, outreach, education, consultation, and management; (2) to participate in blood safety monitoring; and (3) to collaborate with consumer organizations to deliver consistent prevention messages.
The core HTC team is comprised of experts from 4 disciplines: a board-certified hematologist who serves as HTC director, a nurse coordinator, a social worker, and a physical therapist. This team consults with subspecialists including those in dentistry, genetics, orthopedics, infectious disease, hepatology, and pharmacy. HTC staffs maintain long-term relationships with patients and families. HTC clinicians extensively educate the parents of newly diagnosed infants, teaching them how to recognize and effectively respond to bleeds. As children develop verbal skills, HTCs involve the children in their own treatment, teaching them self-infusion skills. 32 This extensive family and patient education promotes normalcy: including the expectation of regular school attendance, physical activity, and employment. HTC clinical services include identification of affected people and families at risk; diagnosis, treatment, self-infusion education, and monitoring; treatment plan development; counseling; case management; rehabilitation; genetic counseling and testing; dental and orthopedic care; nutritional and vocational counseling; and assessing and providing treatment and/or referrals for secondary conditions including hepatitis and HIV/AIDS. HTC community services include linkage with primary care practitioners, financial counselors, and insurance programs; referral to local NHF chapters; and educating and consulting with community providers, and school personnel via satellite clinics, telephone, telemedicine, and grand rounds. HTCs conduct research to develop new therapies, determine optimal treatment protocols, reduce complications, and determine the cost of care. HTC services reach isolated communities including the Amish; reservation-based American Indians; and residents of Alaska and Guam.
33 HTC team members educate and advise policy makers. All of these services aim to improve the quality of life and lengthen the life span ( Figure 3 ). plasma sample bank for rapid investigation of new threats to the blood supply. UDC data are collected annually for all consenting patients seen at HTCs.
Regional HTC Network Administration
The 12 regional HTC networks are administered through the leadership of a regional director and regional coordinator. The regional director is typically an HTC medical director, chosen by consensus for his or her leadership skills. Regional coordinator professional backgrounds include nursing, public health, social work, and law. Regional director/regional coordinator responsibilities were recently standardized in 2001 and embrace both HRSA and CDC duties. These leaders identify and respond to gaps in services via needs assessments, program planning, capacity building, technical assistance, data analysis, and site visits. They promote partnerships between HTCs, state health departments, and local chapters of the NHF. They preside over regional executive committees and foster intraregional communication and referrals. Regional coordinators write and monitor grants; provide fiscal management; oversee annual data collection, analysis, and evaluation; orient new HTC staff; and organize annual clinical education conferences. As regional points of contact and information, regional coordinators rapidly disseminate and replicate best practices, protocols, and new programs and efficiently mobilize HTCs and consumer leadership to respond to emerging health, economic, and social issues.
Because of the limited number of hemophilia experts, capacity building is critical. Regions use many cost-effective strategies to foster skill development and professional networking across institution and state boundaries. The strategies include regional conferences, discipline-specific work groups, listservers, shadowing HTC clinics, and linking mentor HTC clinicians with newly hired colleagues. The regional approach maximizes scarce resources, serving a key role in supporting the hemophilia health care and public health workforce. Regionalization reduces professional isolation and thereby enhances retention, improving the continuity of care. Shared goals, standards, philosophy, and a regional identity foster cooperation and referrals among HTCs, assisting patients who are traveling, going off to college, or relocating.
Multilevel Health Policy Collaboration
The regional infrastructure, HTC collaboration with the NHF and its local chapters and the strong relationships built over the past 30 years makes the hemophilia community effective health policy advocates. Leaders monitor and, together, take action at local, state, and federal levels to improve access to HTCs, strengthen insurance and reimbursement, and enhance coordination with state Title V and Medicaid programs. Hemophilia care is expensive, costing an average of $140 000 annually for a severely affected adult (1995 dollars). 35 More than 90% of the cost of hemophilia care is in treatment products. 35 Improved technology and an extremely limited market has caused a continued rise in costs, 36 thereby requiring ongoing advocacy efforts. The regional network of HTCs for hemophilia is the result of decades long collaboration between patients and their families, health care professionals, and federal public servants who all believe that an organized special care system is imperative to improve the health of affected people. The NHF, founded in 1948, was the first national hemophilia advocacy organization in the US. It was and continues to be instrumental in securing and sustaining federal funding for US HTCs. The NHF partners with HTC clinicians to develop national guidelines for treatment and health care policy. The NHF is the central point for information for people with hemophilia in the United States. Through its more than 45 chapters, the NHF provides the infrastructure for family support networks, advocacy, and education.
The NHF has a Medical and Scientific Advisory Council (MASAC) comprised of the leading bleeding disorder physicians and researchers in the United States. MASAC recommendations set guidelines for care for people with bleeding disorders. MASAC also has representation from HTC nurses, social workers, and physical therapists; patients; and government liaisons including the HRSA, CDC, National Institutes of Health (NIH), and US Food and Drug Administration.
The committee structure of NHF also supports the regional HTC model. Committees are organized to address national issues and develop strategies to meet constituent needs for highquality medical and health care, information, and support services. NHF has working groups for HTC nurses, social workers, and physical therapists. Each consists of a representative from the 12 HTC regions. The working groups' deliberations bolster the rapid dissemination of model programs and practices throughout the United States.
The NHF secures funding from private and public sources for basic science, gene therapy, clinical research, educational programs, and materials. These sources include the HRSA, CDC, and NIH National Heart, Lung and Blood Institute and other institutes, private foundations, and corporations. Consumers, HTC clinicians, and regional coordinators serve on blood safety advisory boards at the US Food and Drug Administration and US Department of Health and Human Service to represent constituent needs ( Figure 4) .
Other key nationwide agencies benefit the hemophilia population and health delivery system. The Hemophilia and Thrombosis
Role
Agency Activities
Logistical and CDC
• The US regional hemophilia model is a highly beneficial, costeffective, and clinically sound approach to health care for people with rare, genetic, chronic bleeding disorders. 47 Its replication holds promise. HTCs care for nearly 8000 women with inherited bleeding disorders, 27,48 and nearly 11 000 people with VWD. 27 Pilot projects were recently initiated to expand the model to people with thalassemia (CDC/HRSA), thrombophilia (CDC), and sickle cell disease (HRSA). Health care leaders and advocates for people who have other rare, expensive, chronic disorders may find a regional approach useful to improve health outcomes and reduce complications. However, they must be clear about the real economic impact: resources are needed from diverse and stable sources to sustain this model in our profitoriented US health care arena. Contributors J. R. Baker originated the symposium which served as the basis of this article, organized the collaboration among authors, and oversaw the concept and article development, including literature review, writing, and editing. S. O. Crudder and B. Riske contributed to concept development, writing, literature review, and editing. V. Bias contributed to the concept development and writing. A. Forsberg contributed to concept development, writing, and editing.
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